The stock of Nurix Therapeutics Inc (NRIX) has seen a -1.40% decrease in the past week, with a 4.07% gain in the past month, and a 20.56% flourish in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are at 5.35% for NRIX. The simple moving average for the last 20 days is 3.64% for NRIX’s stock, with a simple moving average of 44.43% for the last 200 days.
Is It Worth Investing in Nurix Therapeutics Inc (NASDAQ: NRIX) Right Now?
Additionally, the 36-month beta value for NRIX is 2.20. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NRIX is 69.75M and currently, short sellers hold a 13.56% ratio of that float. The average trading volume of NRIX on November 15, 2024 was 745.02K shares.
NRIX) stock’s latest price update
The stock price of Nurix Therapeutics Inc (NASDAQ: NRIX) has dropped by -1.07 compared to previous close of 27.15. Despite this, the company has seen a fall of -1.40% in its stock price over the last five trading days. globenewswire.com reported 2024-10-31 that SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in November:
Analysts’ Opinion of NRIX
Many brokerage firms have already submitted their reports for NRIX stocks, with UBS repeating the rating for NRIX by listing it as a “Buy.” The predicted price for NRIX in the upcoming period, according to UBS is $35 based on the research report published on October 24, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see NRIX reach a price target of $41. The rating they have provided for NRIX stocks is “Buy” according to the report published on October 11th, 2024.
Robert W. Baird gave a rating of “Outperform” to NRIX, setting the target price at $26 in the report published on September 06th of the current year.
NRIX Trading at 9.41% from the 50-Day Moving Average
After a stumble in the market that brought NRIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.13% of loss for the given period.
Volatility was left at 5.35%, however, over the last 30 days, the volatility rate increased by 5.20%, as shares surge +8.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.90% upper at present.
During the last 5 trading sessions, NRIX fell by -1.40%, which changed the moving average for the period of 200-days by +240.00% in comparison to the 20-day moving average, which settled at $25.92. In addition, Nurix Therapeutics Inc saw 160.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NRIX starting from Ring Christine, who sale 3,290 shares at the price of $25.00 back on Nov 04 ’24. After this action, Ring Christine now owns 28,084 shares of Nurix Therapeutics Inc, valued at $82,250 using the latest closing price.
CHRISTINE RING, the Officer of Nurix Therapeutics Inc, proposed sale 3,290 shares at $24.47 during a trade that took place back on Nov 04 ’24, which means that CHRISTINE RING is holding shares at $80,506 based on the most recent closing price.
Stock Fundamentals for NRIX
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.72 for the gross margin
The net margin for Nurix Therapeutics Inc stands at -3.14. The total capital return value is set at -0.45. Equity return is now at value -57.96, with -43.07 for asset returns.
Based on Nurix Therapeutics Inc (NRIX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -15.58. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -24.56.
Currently, EBITDA for the company is -141.41 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 32.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.28.
Conclusion
In conclusion, Nurix Therapeutics Inc (NRIX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
